UC-961, a humanized monoclonal antibody for ROR1 has shown potency in chronic lymphocytic leukemia, ovarian cancer, B-cell lymphoma and breast cancer35–37 (clinical trials: NCT03088878, NCT02860676, NCT02222688, NCT02776917). This evidence concerns the gene ROR1 and ovarian carcinoma.